Human immunodeficiency virus-1 (HIV-1)-Tat, the transactivating gene product of HIV-1, has been shown to interact with different cell types, inducing gene expression, altering their growth and migratory behavior. In this study we examined whether Tat might affect functions of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin’s lymphoma (NHL), relevant to the in vivo dissemination. Our results show that Tat significantly augmented the motility of the two AIDS-related Burkitt’s lymphoma cell lines (AS283 and PA682PB) and AIDS-primary effusion lymphoma cell line (HBL-6-AIDS-PEL). Mutations in RGD or basic domain of Tat (KGE-MBP and LxI-MBP, respectively) sharply reduced migration compared with wild type, suggesting that both domains are required for migration. In contrast, a Tat protein mutation outside the active domains (NH2-TAT-GST) did not reduce lymphoma cell migration. The treatment of lymphoma cells with Tat did not influence their adhesion to matrix proteins or to human vascular endothelial cells, but endothelial cells treated with Tat became more adhesive to lymphoma cells. Flow cytometric analysis showed that treatment of endothelial cells with Tat induced the cell surface expression of the adhesion molecules vascular cell adhesion molecule-1 (VCAM-1) and E-selectin and increased the expression of intercellular adhesion molecule-1 (ICAM-1). Only antibodies against VCAM-1 on endothelial cells or against the VLA-4 integrin expressed on AS283 cells inhibited the increment of adhesion, indicating the relevance of this pathway in the adhesion of lymphoma cells to vascular endothelium. In our work, we show for the first time that Tat can enhance the migration of lymphoma cells and their adhesion to endothelial cells, two processes that may contribute to the malignant behavior of NHL in patients with AIDS.

NON-HODGKIN’S LYMPHOMA (NHL) represents one of the most frequent complications in acquired immunodeficiency syndrome (AIDS).1,2 The majority of AIDS-related NHLs are diffused aggressive B-cell lymphomas with extranodal involvement of the central nervous system in particular.1,3 Their histology includes four categories, namely small noncleaved-cell (including Burkitt’s lymphoma), large-cell immunoblastic plasmocytoid, anaplastic-large cell, and AIDS-related body-cavity–based lymphoma.1,4 Small noncleaved-cell lymphomas are characterized by activating mutations ofc-myc, frequent alterations of p53, and occasional Epstein-Barr virus infection.5,6 Large cell subtype lymphomas are strictly associated with Epstein-Barr virus infection and with rearrangements of c-myc and BCL-6.5,7Finally, AIDS-related body-cavity–based lymphoma is consistently associated with the coinfection of human herpesvirus type-8 and Epstein-Barr virus,8 whereas the anaplastic subtype has not been studied extensively. A feature common to the four AIDS-NHL subtypes is the presence of mutations in the noncoding region ofBCL-6 in the proximity of the gene promoter.9 

The mechanism by which AIDS-NHL cells home into the central nervous system is largely unknown and could involve signals from endothelial cells of blood-brain barrier infected by human immunodeficiency virus-1 (HIV-1)10,11 or specific chemoattractants for lymphoma cells. Microvascular endothelial cells originated from the brain or the bone marrow and infected by HIV-1 support the growth and the adhesion of neoplastic B cells through the surface expression of CD40 that binds CD40 ligand present on lymphoma cells.12 Tat is a potent inducer of the expression of endothelial cell adhesion molecules, including vascular cell adhesion molecule-1 (VCAM-1)13that is involved in the migration of B cells to and within the germinal center of lymphonodes.14 

Tat is a viral protein that transactivates viral genes and increases the replication rate of virion.15 Tat is also able to regulate the expression of host genes, including tumor necrosis factors α and β, interleukin-2 (IL-2), IL-6, major histocompatibility complex of class I, IL-2 receptor, p53 tumor suppressor gene,c-fos, and superoxide dismutase in T cells.16-22Tat can also be released by infected cells, regardless of whether these cells are alive or not,23,24 and extracellular Tat acts as a cytokine-like molecule with a broad range of activities on mesenchymal cells.13,25-33 One of the most striking effects of Tat on vascular endothelial cells is the induction of functions related to angiogenesis and inflammation, including migration, proliferation, and expression of adhesion molecules.13,31 34-36 

Furthermore, it has been recently shown that Tat activates the migration and the tissue invasion of monocytes.27,29Finally, Huang et al have reported that Tat regulates the expression of Fas in B cells.32 

In light of the fact that the infection is a key event in the progression of AIDS-NHLs12 and the viral product Tat can influence the functions of B cells32 and vascular endothelial cells,13,31 34-36 we have investigated whether Tat regulates the homing mechanisms of AIDS-NHL cells.

Cells.

The AS283 and PA682PB AIDS-related Burkitt’s lymphoma and KD488 Burkitt’s lymphoma cell lines were obtained through the courtesy of Dr I.T. Magrath (National Cancer Institute, Bethesda, MD) and are described by Kiwanuka et al.37 The Namalwa and BJAB Burkitt’s lymphoma, the diffuse histocytic lymphoma-4 (DHL-4) follicular lymphoma, and the Capo Epstein-Barr virus (EBV)–transformed lymphoblastoid cell lines were all obtained from Dr J. Golay (Mario Negri Institute, Milan, Italy). We also used the HBL-6-AIDS-primary effusion lymphoma cell line (HBL-6-AIDS-PEL) obtained from Dr G. Gaidano (University of Piemonte Orientale “A. Avogadro”, Turin, Italy). All these lines were maintained in suspension in RPMI 1640 supplemented with 2 mmol/L glutamine and 10% fetal calf serum (FCS) 3T3-NIH mouse fibroblasts (American Type Cell Collection, Bethesda, MD) and human vascular smooth muscle cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 2 mmol/L glutamine and 10% FCS.

Endothelial cells (EC) were isolated from human umbilical vein as previously described38 and maintained in medium 199 supplemented with 10% FCS, 10% newborn calf serum, 50 μg/mL endothelial growth supplement (crude extract from bovine brain), 100 μg/mL heparin, and 20 mmol/L HEPES. All culture reagents were from GIBCO (Paisley, Scotland).

Preparation and biological activity of HIV-1-Tat molecules.

The 358-bp Pst I-BamHI fragment of Tat gene containing exon I and II was kindly donated by Dr A. Caputo (Institute of Microbiology, University of Ferrara, Ferrara, Italy) and has been subcloned in the pMAL-c2 vector (New England Biolabs, Beverly, MA) and then expressed in Escherichia coli according to the manufacturer’s instructions. Tat fused to the maltose binding protein (Tat-MBP) was purified by affinity chromatography on amylose resin and used as fusion proteins. The purified protein gave a unique band detected by silver staining (Gelcode; Pierce Chemical Co, Rockford, IL) after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE); 10%) and was able to induce transcriptional activation of HIV-1 long terminal repeat (LTR) in HL3T1 cells that contain the bacterial gene of chloramphenicol acetyltransferase (CAT) directed by HIV-1 LTR.39 Tat-MBP dose dependently stimulated CAT expression. Briefly, in prewarmed phosphate-buffered saline (PBS), our Tat-MBP preparation was added to confluent HL3T1 cells in a 100-mm diameter dish. Cells were immediately scraped from the plastic surface, then resuspended in fresh medium and centrifuged. The cells were again plated in CO2 incubator, and a CAT assay was performed after 6 hours according to Ausubel et al.40 In our experimental condition, just scraping of the cells in absence of Tat-MBP had no effect on LTR-directed CAT gene expression (125 ± 56 [3H]acetylated chloramphenicol, n = 3). However, CAT gene expression was markedly elevated in cells that received Tat-MBP (0.5 μg/mL: 423 ± 86 [3H]acetylated chloramphenicol; 1 μg/mL: 2,345 ± 167 [3H]acetylated chloramphenicol; 5 μg/mL: 6,543 ± 567 [3H]acetylated chloramphenicol).

Tat-MBP was also active in terms of the migration of Kaposi’s sarcoma cells, human vascular endothelial cells, and human monocytes.27,31,41 For mutagenesis, cDNA Tat was subcloned in the pALTER-Ex1 vector (Promega, Madison, WI). Side-direct mutagenesis was performed with the altered sites mutagenesis kit (Promega) by using mutant oligonucleotides (synthesized by TibMol-Biol, Genova, Italy) to introduce specific mutations (KGE-MBP [Tat-R78K/D80E]: 5′ CCC GAG GGG AAC CGA CAG GCC 3′ and 5′ ACC TCC CAA TCC AAA GGG GAA CCG AC 3′; LXI-MBP [Tat-G49/I50]: 5′ CTC CTA TGG CGG GAT CAA GCG GAG ACA 3′ and 5′ CGG GAT CAA GCT AAT ACA GCG ACG AAG 3′). Specific mutations induced in the cDNA were verified by DNA sequencing by using Sequenase method (Amersham, Buckinghamshire, UK). The mutated cDNAs (356-bp salI-BamHI fragments), subcloned into the pMAL-c2 vector, expressed in E coli as fused protein and purified as described above. NH2-TAT-GST, lacking the first 21 NH2 amino acids, and GST protein were prepared as described.42 

Wild-type Tat-MBP, the mutated proteins, and MBP were lipolysaccharide-free, assessed by Limulus assay (Sigma Chemical Co, St Louis, MO). Proteins were stored at −80°C in the dark, in buffered-phospate saline containing 0.1 mmol/L ZnCl2, 0.1% human serum albumin (Farma Biagini, Lucca, Italy), and 1 mmol/L dithiothreitol.

Reagents.

Human recombinant IL-1β (IL-1; specific activity, 107U/mg) was obtained from BASF, Bioresearch Corp (Cambridge, MA). Monoclonal antibodies to VCAM-1 (CD106; clone 4B2), E-selectin (CD62A; clone 13D5), intercellular adhesion molecule-1 (ICAM-1) (CD54; clone 11C8/1), and α4β1 (VLA-4;CD49d/CD29; clone 2B4) were obtained from British Biotech Pharmaceuticals Ltd (Oxford, UK). Anti-α5β1 (CD49e/CD29; clone SAM-1) was obtained from Immunotech S.A. (Marseille, France), and monoclonal antibodies to αvβ3 (CD51/CD61; clone LM609) and αvβ5 (CD51/CD-; clone P1F6) were purchased from Chemicon (Temecula, CA). Monoclonal antibodies to αLβ2 (lymphocyte function-associated antigen-1 [LFA-1]; CD11a/CD18) were a kind gift from Dr A. Rambaldi (Ospedali Riuniti, Bergamo, Italy). Recombinant soluble VCAM-1 and E-selectin were obtained from Dr J. Clements (British Biotech Pharmaceuticals Ltd). Heparin was purchased from Sigma. Monoclonal antibody to Tat (clone 15.1) was from Intracel (London, UK).

Chemotaxis.

Chemotaxis was conducted in the Boyden chamber, as described previously.43 Different dilutions of Tat-MBP, KGE-MBP, LxI-MBP, MBP, NH2-Tat-GST, and GST with 0.5 μg/mL heparin were added to the lower compartment of the chamber. To block the chemotactic effect of Tat, Tat proteins were mixed with monoclonal antibodies to Tat (dilution 1:50), or Tat proteins were boiled for 10 minutes and then added to the lower compartment of the chamber. Eight-micrometer pore size polyvinylpyrrolidone (PVP)-free polycarbonate Nucleopore filters (Costar, New York, NY) were coated with gelatin by immersing them overnight in a solution of 100 μg/mL gelatin in 0.1% acetic acid and then air dried. The filter separated the attractants from the upper part of the chamber in which AS283 cells were added. After 4 hours of incubation at 37°C, filters were stained with Diff-Quick (Merz-Dade, Dudingen, Switzerland), and the migrated cells in 20 high-power fields were counted. Checkerboard analysis of the chemotactic response was performed by varying the concentrations of Tat-MBP in the upper and lower compartment of the Boyden chamber, as described previously.43 

Adhesion assay.

EC grown to confluent monolayers in 96-well plates were activated for 4 hours with the indicated concentrations of Tat-MBP, KGE-MBP, LxI-MBP, or MBP diluted in culture medium. IL-1 at 2 ng/mL was used as a reference control to activate EC.44 After incubation, monolayers were washed twice, and wells were refilled with 50 μL medium 199 containing 1% bovine serum albumin (BSA; test medium). AS283 cells were radiolabeled with [125I]-Iododeoxyuridine (Amersham), as described previously.45 Fifty microliters of the cell suspension (3 × 104 cells) was added to each well and incubated at 37°C for 30 minutes. After incubation, nonadherent cells were removed by careful aspiration and three washes with test medium. Wells were incubated for 10 minutes with 100 μL of 0.1 mol/L NaOH, and the lysate was counted in a gamma counter.

To test the adhesion of AS283 cells on purified VCAM-1, 96-well plates (Falcon Pro-bind; Becton Dickinson Labware, Franklin Lakes, NJ) were coated with soluble VCAM-1 by adding 50 μL of protein (5 μg/mL) and incubating them overnight at 4°C. After two washes in PBS, the coated surfaces were incubated for 1 hour with PBS containing 1% BSA and then used for the adhesion assay according to the procedure described above.

To test the involvement of adhesion molecules expressed on EC and AS283 cells in the adhesion assays, activated EC were preincubated with test medium alone or containing 20 μg/mL monoclonal antibody (MoAb) anti–VCAM-1, anti–E-selectin, or anti–ICAM-1. Lymphoma cells were preincubated with test medium with or without 20 μg/mL MoAb anti–VLA-4 or anti–LFA-1 for 30 minutes at 37°C before the adhesion assay.

Adhesion was expressed as the percentage of attached tumor cells relative to the total added cells.

Flow cytometric analysis.

EC and AS283 cells were treated for 4 hours with Tat-MBP (20 ng/mL), equimolar concentrations of MBP or IL-1 (2 ng/mL). The expression of adhesion molecules on EC and AS283 cells was measured by indirect immunofluorescence using a FACSort (Becton Dickinson). After incubation with the appropriate primary antibody (1:50 dilution) in PBS with 2.5% FCS for 30 minutes at 4°C, cells were washed and incubated with an affinity-purified fluorescein isothiocyanate (FITC)–labeled goat antimouse Ig antiserum for 30 minutes at 4°C (Tecno Genetics, Italy). Cells were washed again and fixed with PBS containing 1% formalin. Results were expressed as percentage positive cells and the mean of the channel fluorescence intensity.

Statistics.

The Student’s t-test was used to determine statistical differences. Statistical significance was set at P < .05.

Induction of AS283 lymphoma cell migration by Tat-MBP.

Tat-MBP (2 to 200 ng/mL) used as chemoattractant stimulate the motility of AS283 cells in a concentration-dependent manner (Fig1). At the optimal concentration of 20 ng/mL Tat-MBP, the number of migrated AS283 cells augmented from 14.5 ± 0.7 in the control wells to 50.5 ± 4.5 in wells with Tat-MBP (3.5-fold increase). The fusion protein MBP alone did not affect migration (Fig 1), nor did heparin alone (data not shown). Similar results were obtained with the AIDS-related lymphoma lines PA682PB and HBL-6-AIDS-PEL, in which 20 ng/mL Tat-MBP induced a 3.1-fold and a 2-fold increase in migration, respectively (Table1). In contrast, the migration of the Burkitt’s lymphomas (KD488, Namalwa, and BJAB), the follicular lymphoma (DHL-4), and the EBV-transformed lymphoblastoid cell line (Capo) was not increased by Tat-MBP (Table 1). Fibroblasts and vascular smooth muscle cells used as a normal cell control did not respond to Tat-MBP (Table 1).

Fig. 1.

Induction of AS283 lymphoma cell motility by Tat-MBP. Motility response of AS283 lymphoma cells to increasing amounts of Tat-MBP (2 to 200 ng/mL). Control medium, Tat-MBP, and MBP were used as attractants in the presence of heparin (0.5 μg/mL). Data are expressed as the number of migrated cells in 20 high-power fields. Columns, mean of three replicates and representative of 1 out of 3 experiments; bars, SD. *P < .001 compared with control.

Fig. 1.

Induction of AS283 lymphoma cell motility by Tat-MBP. Motility response of AS283 lymphoma cells to increasing amounts of Tat-MBP (2 to 200 ng/mL). Control medium, Tat-MBP, and MBP were used as attractants in the presence of heparin (0.5 μg/mL). Data are expressed as the number of migrated cells in 20 high-power fields. Columns, mean of three replicates and representative of 1 out of 3 experiments; bars, SD. *P < .001 compared with control.

Close modal
Table 1.

Induction of Lymphoma Cell Migration by Tat-MBP

Cell Type Cell LineChemoattractant
None Tat-MBP Positive Control
AIDS-Burkitt’s lymphoma  AS283  14 ± 2 50 ± 4* 216 ± 41-a 
 PA682PB 11 ± 1  35 ± 6* 29 ± 71-a 
Burkitt’s lymphoma  KD488  35 ± 6  34 ± 4 72 ± 81-a 
 Namalwa  6 ± 2 2 ± 1  235 ± 31-a 
 BJAB  7 ± 2 1 ± 1  14 ± 61-b 
AIDS-primary effusion lymphoma  HBL-6-AIDS-PEL  15 ± 8  30 ± 4* 56 ± 401-b 
Follicular lymphoma  DHL-4 8 ± 1  8 ± 1  110 ± 261-a 
EBV-transformed lymphoblastoid  Capo  3 ± 0  5 ± 2 107 ± 261-a 
Fibroblasts  3T3-NIH  8 ± 4 11 ± 5  55 ± 121-c 
Vascular smooth muscle cells  VSMC  16 ± 5  12 ± 3 85 ± 121-c 
Cell Type Cell LineChemoattractant
None Tat-MBP Positive Control
AIDS-Burkitt’s lymphoma  AS283  14 ± 2 50 ± 4* 216 ± 41-a 
 PA682PB 11 ± 1  35 ± 6* 29 ± 71-a 
Burkitt’s lymphoma  KD488  35 ± 6  34 ± 4 72 ± 81-a 
 Namalwa  6 ± 2 2 ± 1  235 ± 31-a 
 BJAB  7 ± 2 1 ± 1  14 ± 61-b 
AIDS-primary effusion lymphoma  HBL-6-AIDS-PEL  15 ± 8  30 ± 4* 56 ± 401-b 
Follicular lymphoma  DHL-4 8 ± 1  8 ± 1  110 ± 261-a 
EBV-transformed lymphoblastoid  Capo  3 ± 0  5 ± 2 107 ± 261-a 
Fibroblasts  3T3-NIH  8 ± 4 11 ± 5  55 ± 121-c 
Vascular smooth muscle cells  VSMC  16 ± 5  12 ± 3 85 ± 121-c 

Motility response of lymphoma cells and non-neoplastic cells to Tat-MBP. Control medium and 20 ng/mL Tat-MBP were used as attractants in the presence of 0.5 μg/mL heparin. Appropriate positive control chemoattractants were used for each single cell line:

F1-a

25 μg/mL fibronectin,

F1-b

conditioned medium of 3T3-NIH cells,

F1-c

5 ng/mL platelet-derived growth factor (PDGF). Data are expressed as the number of migrated cells ± SD in 20 high-power fields. Data are the mean of three replicates and representative of 1 of 2 experiments minimum.

*

P < .001.

Checkerboard analysis showed that Tat-MBP mainly induced a directional motility response of AS283 lymphoma cells, although a chemokinetic component was also present (Fig 2).

Fig. 2.

Checkerboard analysis of AS283 motility response to Tat-MBP. Different gradient conditions were obtained by adding the indicated concentrations of Tat-MBP to the upper and lower compartments of the Boyden chamber. Cells, in the upper compartment, were exposed to conditions of null gradient (same concentration of Tat-MBP in the upper and lower compartments, diagonal), positive gradients (higher concentrations of Tat-MBP in the lower compartment, below the diagonal), or negative gradients (higher concentrations of Tat-MBP in the upper compartment, above the diagonal). Data are expressed as the number of migrated cells in 20 high-power fields (mean and SD of triplicates).

Fig. 2.

Checkerboard analysis of AS283 motility response to Tat-MBP. Different gradient conditions were obtained by adding the indicated concentrations of Tat-MBP to the upper and lower compartments of the Boyden chamber. Cells, in the upper compartment, were exposed to conditions of null gradient (same concentration of Tat-MBP in the upper and lower compartments, diagonal), positive gradients (higher concentrations of Tat-MBP in the lower compartment, below the diagonal), or negative gradients (higher concentrations of Tat-MBP in the upper compartment, above the diagonal). Data are expressed as the number of migrated cells in 20 high-power fields (mean and SD of triplicates).

Close modal

To identify the molecular domain of Tat responsible for the stimulation of AS283 motility, we tested two mutated Tat-MBP proteins, one mutated in the RGD domain (KGE-MBP) and one in the basic domain (LxI-MBP). Figure 3A shows that KGE-MBP and LxI-MBP have drastically lost the ability to induce the migration of AS283 cells. Even higher concentrations of the two mutated Tat-MBP proteins did not influence the migration of lymphoma cells (data not shown). These data indicate that the chemotactic properties of Tat-MBP might be dependent on a collaboration between the RGD and the basic domains. A Tat protein mutated in the apparently noninvolved N-terminal domain was also used (NH2-Tat-GST). NH2-Tat-GST showed similar activity on AS283 cell migration as did Tat-MBP (Fig 3B). The fusion protein GST alone had no effect at all. The specificity of Tat-MBP has been confirmed by the finding that neutralizing antibodies against Tat and heat inactivation blocked its activity on AS283 cell motility (Fig 4A). Similar results were obtained using NH2-Tat-GST (Fig 4B).

Fig. 3.

Chemotactic activity of mutated Tat proteins. (A) Inhibition of AS283 lymphoma cell motility by mutated Tat-MBP proteins. KGE-MBP and LxI-MBP proteins are mutated, respectively, in the RGD and basic domain of Tat. (B) AS283 lymphoma cell motility induced by a Tat protein mutated in the N-terminal domain. Each protein was tested at the concentration of 20 ng/mL. MBP or GST alone were used at the equimolar concentration. Data are expressed as the number of migrated cells in 20 high-power fields. Columns, mean of three replicates and representative of 1 out of 3 experiments; bars, SD. *P < .05 compared with corresponding control.

Fig. 3.

Chemotactic activity of mutated Tat proteins. (A) Inhibition of AS283 lymphoma cell motility by mutated Tat-MBP proteins. KGE-MBP and LxI-MBP proteins are mutated, respectively, in the RGD and basic domain of Tat. (B) AS283 lymphoma cell motility induced by a Tat protein mutated in the N-terminal domain. Each protein was tested at the concentration of 20 ng/mL. MBP or GST alone were used at the equimolar concentration. Data are expressed as the number of migrated cells in 20 high-power fields. Columns, mean of three replicates and representative of 1 out of 3 experiments; bars, SD. *P < .05 compared with corresponding control.

Close modal
Fig. 4.

Inactivation of chemotactic activity of Tat. Monoclonal antibodies against Tat (dilution 1:50) were mixed with Tat proteins, or Tat proteins were boiled for 10 minutes and then added to the lower compartment of the chamber. Tat-MBP and NH2-Tat-GST were used in (A) and (B), respectively. Each protein was tested at the concentration of 20 ng/mL. Data are expressed as the number of migrated cells in 20 high-power fields. Columns, mean of 3 replicates (and representative of 1 out of 2 experiments done); bars, SD. *P< .001 compared with Tat-MBP without treatment, **P < .05 compared with NH2-Tat-GST without treatment.

Fig. 4.

Inactivation of chemotactic activity of Tat. Monoclonal antibodies against Tat (dilution 1:50) were mixed with Tat proteins, or Tat proteins were boiled for 10 minutes and then added to the lower compartment of the chamber. Tat-MBP and NH2-Tat-GST were used in (A) and (B), respectively. Each protein was tested at the concentration of 20 ng/mL. Data are expressed as the number of migrated cells in 20 high-power fields. Columns, mean of 3 replicates (and representative of 1 out of 2 experiments done); bars, SD. *P< .001 compared with Tat-MBP without treatment, **P < .05 compared with NH2-Tat-GST without treatment.

Close modal
Induction of EC adhesiveness by Tat-MBP.

The adhesion of AS283 lymphoma cells was significantly increased on EC activated with Tat-MBP for 4 hours with maximal stimulation at 20 ng/mL Tat-MBP (Fig 5). Tat-MBP induced approximately a 1.6-fold increase of adhesion, reproducible in all the experiments performed. MBP alone had no effect.

Fig. 5.

Adhesion of AS283 lymphoma cells to endothelial cells activated with Tat-MBP. AS283 lymphoma cell adhesion was tested on EC activated with different concentrations of Tat-MBP. EC were treated with medium alone (control), Tat-MBP (20 to 200 ng/mL), or equimolar concentration of MBP. EC were activated for 4 hours, and adhesion of AS283 lymphoma cells was evaluated after 30 minutes. Results show attached cells as a percentage of total added cells. Columns, mean of three replicates and representative of 1 of 3 experiments; bars, SD. *P < .01 compared with control.

Fig. 5.

Adhesion of AS283 lymphoma cells to endothelial cells activated with Tat-MBP. AS283 lymphoma cell adhesion was tested on EC activated with different concentrations of Tat-MBP. EC were treated with medium alone (control), Tat-MBP (20 to 200 ng/mL), or equimolar concentration of MBP. EC were activated for 4 hours, and adhesion of AS283 lymphoma cells was evaluated after 30 minutes. Results show attached cells as a percentage of total added cells. Columns, mean of three replicates and representative of 1 of 3 experiments; bars, SD. *P < .01 compared with control.

Close modal

We therefore investigated by fluorescence-activated cell sorter (FACS) analysis whether the increased adhesiveness was sustained by an increment of adhesion molecules. Twenty nanograms/milliliter Tat-MBP induced the expression of E-selectin and VCAM-1 and increased the expression of ICAM-1 after 4 hours of activation (Table2). MBP alone had no significant effect on the expression of adhesion molecules. The increment of lymphoma cell adhesion to EC treated with Tat-MBP was lower compared with IL-1–activated EC, used as a positive control (3.1-fold increase of adhesion). The treatment of EC together with Tat-MBP did not have any additional effect with regards to enhancing AS283 cell adhesion (data not shown). Accordingly, Tat-MBP was less potent than IL-1 in augmenting the expression of adhesion molecules on EC (Table 2). Increasing the concentration of Tat-MBP had no further effect on the expression of these adhesion molecules. Treatment of AS283 cells with Tat-MBP did not increase their adhesion to EC (data not shown). Indeed, adhesion molecules such as ICAM-1, LFA-1, and VLA-4 expressed on AS283 cells did not change after Tat-MBP (20 ng/mL) treatment (data not shown). Similar to that of the AS283 cells, the adhesion of PA682PB cells was also augmented on EC activated by Tat-MBP (data not shown).

Table 2.

Induction of Adhesion Molecules on EC by Tat-MBP

Antigen Endothelial-Cell Treatment*
Control IL-1 Tat-MBP MBP
ICAM-1 69 (65) 99 (347)  78 (128)  79 (84)  
E-selectin 4 (55)  91 (209)  66 (102)  7 (56)  
VCAM-1 1 (23)  45 (26)  13 (33)  3 (17) 
Antigen Endothelial-Cell Treatment*
Control IL-1 Tat-MBP MBP
ICAM-1 69 (65) 99 (347)  78 (128)  79 (84)  
E-selectin 4 (55)  91 (209)  66 (102)  7 (56)  
VCAM-1 1 (23)  45 (26)  13 (33)  3 (17) 

Results represent one typical experiment out of three performed.

*

EC were treated for 4 hours with medium (control), IL-1 (2 ng/mL), Tat-MBP (20 ng/mL), or equimolar concentrations of MBP.

Results (determined by FACS analysis) are expressed as the percentage of positive cells and the mean channel of fluorescence intensity.

To identify the adhesion molecules involved in AS283/EC adhesion, EC were treated with antibodies against VCAM-1, E-selectin, and ICAM-1. Only antibodies against VCAM-1 blocked the increased adhesion of AS283 cells to EC (Fig 6A). Antibodies against E-selectin and ICAM-1 had no effect on the adhesion to EC (Fig 6A). To confirm that AS283 cell adhesion on Tat-MBP–activated EC depended on the VCAM-1/VLA-4 interaction, we found that AS283 cells selectively attached themselves to VCAM-1–coated plastic, and this adhesion could be blocked by antibodies against VLA-4 to tumor cells (Fig 6B).

Fig. 6.

(A) Inhibition of AS283 lymphoma cell adhesion to Tat-activated EC. EC were treated for 4 hours with medium alone (control) or Tat-MBP (20 ng/mL) and thereafter incubated with antibodies against the adhesion molecules E-selectin, VCAM-1, and ICAM-1. Adhesion of AS283 lymphoma cells was evaluated after 30 minutes. (B) AS283 lymphoma cell adhesion to VCAM-1. Wells were coated with 5 μg/mL VCAM-1 or buffer only (control). AS283 cells treated or not with antibodies against VLA-4 were incubated on soluble VCAM-1–coated plastic for 30 minutes. Results show the attached cells as a percentage of total cells added. Columns, mean of three replicates and representative of 1 of 3 experiments; bars, SD. *P< .05 compared with EC treated with Tat-MBP without MoAb (A) or to VCAM-1 (B).

Fig. 6.

(A) Inhibition of AS283 lymphoma cell adhesion to Tat-activated EC. EC were treated for 4 hours with medium alone (control) or Tat-MBP (20 ng/mL) and thereafter incubated with antibodies against the adhesion molecules E-selectin, VCAM-1, and ICAM-1. Adhesion of AS283 lymphoma cells was evaluated after 30 minutes. (B) AS283 lymphoma cell adhesion to VCAM-1. Wells were coated with 5 μg/mL VCAM-1 or buffer only (control). AS283 cells treated or not with antibodies against VLA-4 were incubated on soluble VCAM-1–coated plastic for 30 minutes. Results show the attached cells as a percentage of total cells added. Columns, mean of three replicates and representative of 1 of 3 experiments; bars, SD. *P< .05 compared with EC treated with Tat-MBP without MoAb (A) or to VCAM-1 (B).

Close modal

It has been found that biological functions of mesenchymal cells, like monocytes and endothelial cells, can be modulated by the HIV-1-Tat protein.20,29,31,34,36 Recently, it has been described that Tat can upregulate Fas expression in B lymphocytes,32suggesting that Tat may contribute to B-cell hyperactivation during HIV infection. Polyclonal hyperactivation and proliferation of B cells has been associated with the development of NHL in AIDS patients.46 In this study, we show that Tat induces the migration of two AIDS-related Burkitt’s lymphoma cell lines (AS283 and PA682PB)37 and increases their adhesiveness to human endothelium, two processes that are required for the spreading of highly malignant AIDS-NHL cells. We also tested other kinds of lymphoma cells and found that only the HBL-6-AIDS-PEL lymphoma cell line migrated against Tat-MBP (Table 1), thus suggesting a selective role for the Tat protein in the migration of lymphomas derived from HIV-infected patients. An extensive study on primary lymphoma cells from patients with AIDS is likely to be necessary to address this hypothesis.

Tat protein has been found extracellularly, and induction of lymphoma cell migration was observed at concentrations that have been detected in AIDS patients.26 Similar concentrations of Tat have been reported to induce monocyte29 and EC31 motility and also to upregulate FAS expression in B cells.32 We therefore propose that secreted Tat can promote lymphoma migration and extravasation into tissues. Tat concentrations detected in the serum of AIDS patients are approximately 1 to 2 ng/mL.31 In our experiments, we observed that concentrations between 2 and 20 ng/mL are able to significantly stimulate cell motility. It is possible that the phenomenon of lymphoma cell recruitment by Tat becomes relevant at sites of Tat production and release, where concentrations are presumably higher than those in the circulation.

Extracellular activities of Tat can be mediated through the RGD-containing region or through the basic domain.31,47 To investigate the role of Tat domains in the induction of lymphoma cell motility, two mutated Tat-MBP proteins were used: the KGE-MBP protein that is mutated in the RGD domain, and the LxI-MBP protein that is mutated in the basic domain. We found that neither the RGD nor the basic domain-mutated Tat protein had any effect on lymphoma cell migration. A third Tat protein, NH2-Tat-GST, which is deleted of the first 21 amino acids and does not contain the cysteine-rich domain, had similar activity on lymphoma migration as Tat-MBP, and the data obtained exclude a role for this domain in Tat-induced lymphomas. These data indicate that the chemotactic properties of Tat for AIDS-related lymphoma cells might require both the RGD and the basic domain of Tat. In contrast, the cysteine-rich domain, which has been recently implicated in monocyte chemotaxis induced by Tat,48 seems to be irrelevant for the motility of lymphoma cells. At variance with our findings, it has been shown that the motility of EC was equally stimulated by synthetic peptides containing both the basic or the RGD domain of Tat,47though angiogenesis in vivo was only induced by the basic peptide.31 The fact that AS283 cells did not express the integrin receptors αvβ3 and α5β1 that recognize the RGD sequence of Tat,35 nor the integrin αvβ5 that binds the basic domain of the Tat protein49 (data not shown), suggests that other ligands are involved in the interaction of Tat with AS283 cells. Altogether, these data indicate that different cell types respond to different domains of Tat. Furthermore, it is also possible that unique Tat domains are responsible for different physiological functions, such as migration in vitro and angiogenesis in vivo on the same cell type.31 47 

We have recently shown that Tat-induced migration of endothelial cells and monocytes occurs through the activation of the high affinity tyrosin kinase receptors for vascular endothelial growth factor (VEGF), VEGFR-2/KDR/Flk-1, and VEGFR-1/Flt-1, respectively.27,31Here we found that VEGF (20 ng/mL) induced AS283 cell migration and that pretreatment of AS283 cells with VEGF resulted in an inhibition of a subsequent response to Tat (data not shown). This result is reminiscent of the observation that VEGF is an autocrine/paracrine growth factor for acute myeloid cells.50 Although these findings indicate that AS283 cell migration induced by Tat and VEGF depended on the same receptor, VEGFR-1/Flt-1 and VEGFR-2/Flk-1/KDR receptors were not expressed on AS283 cells as analyzed by Northern blot analysis (data not shown). This may indicate the presence of another receptor on AS283 cells. Recently, a third VEGF coreceptor, identical to human neuropilin-1, has been described on endothelial cells and different types of tumor cells.51 Whether this or another receptor is responsible for Tat-induced lymphoma cell motility needs further investigation.

Another important event in the lymphoma dissemination is the interaction between tumor cells and vascular endothelial cells. We show that the treatment of EC with Tat enhances their adhesiveness to lymphoma cells. The upregulation of ICAM-1, VCAM-1, and E-selectin on EC after Tat treatment has been previously shown.13 The role of VCAM-1 and ICAM-1 in the adhesion of B lymphocytes has been shown.52,53 Here we show that the augmented adhesion of AS283 lymphoma cells to Tat-activated EC is mainly associated with an increased expression of VCAM-1, and this is abolished only by antibodies against anti–VCAM-1, but not against ICAM-1. Accordingly, two different reports have shown that lymphocyte adhesion (including Burkitt’s lymphoma cell) to cytokine-activated EC is preferentially mediated by the upregulation of VCAM-1.54,55 The lack of adhesion of Burkitt’s lymphoma to ICAM-1 expressed on endothelial cells is explained by Patarroyo et al.56 They compared a panel of 10 lymphoblastoid cell lines with 10 Burkitt’s lymphoma for the expression of LFA-1 and found that Burkitt’s lymphoma expresses only low levels of this integrin, whereas lymphoblastoid cell lines, representing various stages of B-lymphocyte development, express considerable levels of LFA-1. Although we found that by FACS analysis our AS283 cell line expressed LFA-1, its adhesion to Tat-activated EC was not abolished by antibodies against LFA-1, supporting further the preferential use of the VCAM-1/VLA-4 pathway in the adhesion to Tat-activated EC. The VCAM-1/VLA-4–dependent adhesion of AS283 has been further shown by completely blocking its adhesion to soluble VCAM-1–coated plastic and by treating AS283 cells with antibodies against VLA-4.

It has been shown that anti-CD40 stimulates the heterotypic adhesion of normal and transformed B cells to EC, and this is mainly mediated by VCAM-1/VLA-4 pathway in alternative to ICAM-1/LFA-1.53Furthermore, it has been found that HIV-infected microvascular EC promotes the attachment and growth of malignant B-cell lymphoma.12 It is worth noting that HIV infection of microvascular EC stimulates the expression of CD40, resulting in preferential induction of VCAM-1 after CD40 triggering,12once again showing the importance of the VCAM-1/VLA-4 pathway. However, we did not find CD40 expression on endothelial cells treated with Tat (data not shown), suggesting that this pathway is not involved in our experimental model.

In conclusion, AIDS-related lymphomas frequently involve extranodal sites, particularly in the gastrointestinal tract and the central nervous system, which represent the primary sites of involvement in a significant fraction of the cases.1-3 5 We showed in this work that HIV-1-Tat can enhance the migration of AIDS-related lymphoma cells and their adhesion to endothelial cells. In AIDS patients, this may contribute to the homing and growth of malignant lymphomas at these extranodal sites.

The authors thank Dr L.T. Magrath (National Cancer Institute, Bethesda, MD), Dr G. Golay (M. Negri Institute for Pharmacological Research, Milan, Italy), and Dr G. Gaidano (University of Piemonte Orientale “A. Avogadro”, Turin, Italy) for providing some of the lymphoma cell lines used in this study.

Supported by grants from the Istituto Superiore di Sanità (AIDS Project and Program on Tumor Therapy), and Associazione Italiana per la Ricerca sul Cancro (AIRC).

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

1
Levine
AM
Acquired immunodeficiency syndrome-related lymphoma.
Blood
80
1992
8
2
Karp
JE
Broder
S
Acquired immunodeficiency syndrome and non-Hodgkin’s lymphomas.
Cancer Res
51
1991
4743
3
Beral
V
Peterman
T
Berkelman
R
Jaffe
H
AIDS-associated non-Hodgkin lymphoma.
Lancet
337
1991
805
4
Knowles
DM
Inghirami
G
Ubriaco
A
Dalla-Favera
R
Molecular genetic analysis of three AIDS-associated neoplasms of uncertain lineage demonstrates their B-cell derivation and the possible pathogenetic role of the Epstein-Barr virus.
Blood
73
1989
792
5
Gaidano
G
Carbone
A
Dalla-Favera
R
Pathogenesis of AIDS-related lymphomas: Molecular and histogenetic heterogeneity.
Am J Pathol
152
1998
623
6
Ballerini
P
Gaidano
G
Gong
JZ
Tassi
V
Saglio
G
Knowles
DM
Dalla-Favera
R
Multiple genetic lesions in acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma.
Blood
81
1993
166
7
Gaidano
G
Lo Coco
F
Ye
BH
Shibata
D
Levine
AM
Knowles
DM
Dalla-Favera
R
Rearrangements of the BCL-6 gene in acquired immunodeficiency syndrome-associated non-Hodgkin’s lymphoma: Association with diffuse large-cell subtype.
Blood
84
1994
397
8
Cesarman
E
Chang
Y
Moore
PS
Said
JW
Knowles
DM
Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas.
N Engl J Med
332
1995
1186
9
Gaidano
G
Carbone
A
Pastore
C
Capello
D
Migliazza
A
Gloghini
A
Roncella
S
Ferrarini
M
Saglio
G
Dalla-Favera
R
Frequent mutation of the 5′ noncoding region of the BCL-6 gene in acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas.
Blood
89
1997
3755
10
Moses
AV
Stenglein
SG
Strussenberg
JG
Wehrly
K
Chesebro
B
Nelson
JA
Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region on the viral genome.
J Virol
70
1996
3401
11
Moses
AV
Bloom
FE
Pauza
CD
Nelson
JA
Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism.
Proc Natl Acad Sci USA
90
1993
10474
12
Moses
AV
Williams
SE
Strussenberg
JG
Heneveld
ML
Ruhl
RA
Bakke
AC
Bagby
GC
Nelson
JA
HIV-1 induction of CD40 on endothelial cells promotes the outgrowth of AIDS-associated B-cell lymphomas.
Nat Med
3
1997
1242
13
Dhawan
S
Puri
RK
Kumar
A
Duplan
H
Masson
J-M
Aggarwal
BB
Human immunodeficiency virus-1-Tat protein induces the cell surface expression of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in human endothelial cells.
Blood
90
1997
1535
14
Freedman
AS
Munro
JM
Rice
GE
Bevilacqua
MP
Morimoto
C
McIntyre
BW
Rhynhart
K
Pober
JS
Nadler
LM
Adhesion of human B cells to germinal centers in vitro involves VLA-4 and INCAM-110.
Science
249
1990
1030
15
Vaishnav
YN
Wong-Staal
F
The biochemistry of AIDS.
Annu Rev Biochem
60
1991
577
16
Westendorp
MO
Shatrov
VA
Schulze-Osthoff
K
Frank
R
Kraft
M
Los
M
Krammer
PH
Droge
W
Lehmann
V
HIV-1 Tat potentiates TNF-induced NF-κB activation and cytotoxicity by altering the cellular redox state.
EMBO J
14
1995
546
17
Siekevitz
M
Feinberg
MB
Holbrook
N
Wong-Staal
F
Greene
WC
Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type 1.
Proc Natl Acad Sci USA
84
1987
5389
18
Scala
G
Ruocco
MR
Ambrosino
C
Mallardo
M
Giordano
V
Baldassarre
F
Dragonetti
E
Quinto
I
Venuta
S
The expression of the interleukin 6 gene is induced by the human immunodeficiency virus I TAT protein.
J Exp Med
179
1994
961
19
Howcroft
TK
Strebel
K
Martin
MA
Singer
DS
Repression of MHC class I gene promoter activity by two-exon Tat of HIV.
Science
260
1993
1320
20
Gibellini
D
Caputo
A
Capitani
S
La Placa
M
Zauli
G
Upregulation of c-Fos in activated T lymphoid and monocytic cells by human immunodeficiency virus-1 Tat protein.
Blood
89
1997
1654
21
Buonaguro
L
Buonaguro
FM
Giraldo
G
Ensoli
B
The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure.
J Virol
68
1994
2677
22
Li
CJ
Wang
C
Friedman
DJ
Pardee
AB
Reciprocal modulations between p53 and Tat of human immunodeficiency virus type 1.
Proc Natl Acad Sci USA
92
1995
5461
23
Ensoli
B
Buonaguro
L
Barillari
G
Fiorelli
V
Gendelman
R
Morgan
RA
Wingfield
P
Gallo
RC
Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.
J Virol
67
1993
277
24
Chang
HC
Samaniengo
F
Nair
BC
Buonaguro
L
Ensoli
B
HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulphate proteoglycans through its basic region.
AIDS
11
1997
1421
25
Zauli
G
Gibellini
D
Celeghini
C
Mischiati
C
Bassini
A
La Placa
M
Capitani
S
Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4+ T lymphocytes.
J Immunol
157
1996
2216
26
Westendorp
MO
Frank
R
Ochsenbauer
C
Stricker
K
Dhein
J
Walczak
H
Debatin
K-M
Krammer
PH
Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120.
Nature
375
1995
497
27
Mitola
S
Sozzani
S
Luini
W
Primo
L
Borstatti
A
Weich
H
Bussolino
F
Tat-human immunodeficiency virus-1 induces human monocyte chemotaxis by activation of vascular endothelial growth factor receptor-1.
Blood
90
1997
1365
28
Lotz
M
Clark-Lewis
I
Ganu
V
HIV-1 transactivator protein Tat induces proliferation and TGFβ expression in human articular chondrocytes.
J Cell Biol
124
1994
365
29
Lafrenie
RM
Wahl
LM
Epstein
JS
Hewlett
IK
Yamada
KM
Dhawan
S
HIV-1-Tat protein promotes chemotaxis and invasive behavior by monocytes.
J Immunol
157
1996
974
30
Ensoli
B
Gendelman
R
Markham
P
Fiorelli
V
Colombini
S
Raffeld
M
Cafaro
A
Chang
H-K
Brady
JN
Gallo
RC
Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi’s sarcoma.
Nature
371
1994
674
31
Albini
A
Soldi
R
Giunciuglio
D
Giraudo
E
Benelli
R
Primo
L
Noonan
D
Salio
M
Camussi
G
Rockl
W
Bussolino
F
The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells.
Nat Med
2
1996
1371
32
Huang
L
Li
CJ
Pardee
AB
Human immunodeficiency virus type 1 TAT protein activates B lymphocytes.
Biochem Biophys Res Commun
237
1997
461
33
Ensoli
B
Barillari
G
Salahuddin
SZ
Gallo
RC
Wong-Staal
F
Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients.
Nature
345
1990
84
34
Hofman
FM
Wright
AD
Dohadwala
MM
Wong-Staal
F
Walker
SM
Exogenous tat protein activates human endothelial cells.
Blood
82
1993
2774
35
Barillari
G
Gendelman
R
Gallo
RC
Ensoli
B
The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence.
Proc Natl Acad Sci USA
90
1993
7941
36
Albini
A
Barillari
G
Benelli
R
Gallo
RC
Ensolo
B
Angiogenic properties of human immunodeficiency virus type 1 Tat protein.
Proc Natl Acad Sci USA
92
1995
4838
37
Kiwanuka
J
Shiramizu
B
Sandlund
T
Barriga
F
McManaway
M
Novikovs
L
Huber
B
Magrath
IT
The contribution of Burkitt’s lymphoma cell lines to the understanding of the pathogenesis of Burkitt’s lymphoma.
Cancer Rev
10
1988
63
38
Jaffe
E
Nachman
R
Becker
C
Minick
C
Culture of human endothelial cells derived from umbilical veins; Identification of morphologic and immunologic criteria.
J Clin Invest
52
1973
2745
39
Whright
CM
Selber
BK
Paskalis
H
Pavlakis
GN
Expression and characterization of the trans activator of HTLV-III/LAV virus.
Science
234
1986
988
40
Kingston
RE
Moore
DD
Isotopic assay for reporter gene activity
Current Protocols in Molecular Biology.
Ausubel
MF
Brent
R
Kingston
RE
Moore
DD
Seidman
JG
Smith
JA
Struhl
K
1995
9.7.A
Wiley
New York, NY
41
Albini
A
Fontanini
G
Masiello
L
Tacchetti
C
Bigini
D
Luzzi
P
Noonan
DM
Stetler-Sevenson
WG
Angiogenic potential in vivo by Kaposi’s sarcoma cell-free supernatants and HIV-1 tat product: Inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2.
AIDS
8
1994
1237
42
Marzio
G
Tyagi
M
Gutierrez
MI
Giacca
M
HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter.
Proc Natl Acad Sci USA
95
1998
13519
43
Taraboletti
G
Roberts
D
Liotta
LA
Giavazzi
R
Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: A potential angiogenesis regulatory factor.
J Cell Biol
111
1990
765
44
Chirivi
RGS
Garofalo
A
Martin-Padura
I
Mantovani
A
Giavazzi
R
Interleukin-1 receptor antagonist inhibits the augmentation of metastasis induced by interleukin-1 or lipopolysaccharide in a human melanoma/nude mouse model.
Cancer Res
53
1993
5051
45
Dejana
E
Bertocchi
F
Bortolami
MC
Regonesi
A
Tonta
A
Breviario
F
Giavazzi
R
Interleukin 1 promotes tumor cell adhesion to cultured human endothelial cells.
J Clin Invest
82
1988
1466
46
McGrath
MS
Shiramizu
B
Meeker
TC
Kaplan
LD
Herndier
B
AIDS-associated polyclonal lymphoma: Identification of a new HIV-associated process.
J Acquir Immune Defic Syndr
4
1991
408
47
Albini
A
Benelli
R
Presta
M
Rusnati
M
Ziche
M
Rubartelli
A
Paglialunga
G
Bussolino
F
Noonan
D
HIV-tat protein is a heparin-binding angiogenic growth factor.
Oncogene
12
1996
289
48
Albini
A
Benelli
R
Giunciuglio
D
Cai
T
Mariani
G
Ferrini
S
Noonan
DM
Identification of a novel domain of HIV tat involved in monocyte chemotaxis.
J Biol Chem
273
1998
15895
49
Vogel
BE
Lee
S-J
Hildebrand
A
Craig
W
Pierschbacher
MD
Wong-Staal
F
Ruoslahti
E
A novel integrin specificity exemplified by binding of the αvβ5 integrin to the basic domain of the HIV Tat protein and vitronectin.
J Cell Biol
121
1993
461
50
Fiedler
W
Graeven
U
Ergun
S
Verago
S
Kilic
N
Stockschlader
M
Hossfeld
DK
Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia.
Blood
89
1997
1870
51
Soker
S
Takashima
S
Miao
HQ
Neufeld
G
Klagsbrun
M
Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.
Cell
92
1998
735
52
Prieto
J
Beatty
PG
Clark
EA
Patarroyo
M
Molecules mediating adhesion of T and B cells, monocytes and granulocytes to vascular endothelial cells.
Immunology
63
1988
631
53
Flores-Romo
L
Estoppey
D
Bacon
KB
Anti-CD40 antibody stimulates the VLA-4-dependent adhesion of normal and LFA-1-deficient B cells to endothelium.
Immunology
79
1993
445
54
Carlos
TM
Schwartz
BR
Kovach
NL
Yee
E
Rosso
M
Osborn
L
Chi-Rosso
G
Newman
B
Lobb
R
Harlan
JM
Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells.
Blood
76
1990
965
55
Rice
GE
Munro
JM
Bevilacqua
MP
Inducible cell adhesion molecule 110 (INCAM-110) is an endothelial receptor for lymphocytes. A CD11/CD18-independent adhesion mechanism.
J Exp Med
171
1990
1369
56
Patarroyo
M
Prieto
J
Ernberg
I
Gahmberg
CG
Absence, or low expression, of leukocyte adhesion molecule CD11 and CD18 on Burkitt lymphoma cells.
Int J Cancer
41
1988
901

Author notes

Address reprint requests to Raffaella Giavazzi, PhD, Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, 24125 Bergamo, Italy; e-mail: giavazzi@irfmn.mnegri.it.

Sign in via your Institution